{"filing":{"accession_number":"0001213900-26-112236","cik":"0002112457","ticker":"AMAN","company_name":"Amanat Acquisition Corp.","form":"8-K","filing_date":"2026-10-26","report_date":"2026-10-25","primary_document":"ea0308954-8k425_amanat.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2112457/000121390026112236/ea0308954-8k425_amanat.htm"},"events":[{"id":37755,"run_id":34794,"accession_number":"0001213900-26-112236","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Amanat Acquisition Corp. entered into a definitive Business Combination Agreement with Corxel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, with an implied Corxel equity value of $200 million and approximately $377 million in gross proceeds. The transaction includes a $300 million PIPE financing and is expected to close in H1 2027, subject to customary conditions including shareholder approval and HSR clearance.","company_name":"Amanat Acquisition Corp.","ticker":"AMAN","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42573,"accession_number":"0001213900-26-112236","item_number":"1.01","item_title":"Entry Into A Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This disclosure documents entry into a definitive Business Combination Agreement between Amanat Acquisition Corp (a SPAC) and Corxel Pharmaceuticals, Inc., involving a merger structure with an implied Corxel equity value of $200 million and approximately $377 million in gross proceeds (including a $300 million PIPE). The transaction is a material acquisition/change of control that will result in Corxel becoming a publicly listed company, with expected closing in H1 2027 subject to customary conditions including shareholder approval and HSR clearance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:14:42.868514+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42575,"accession_number":"0001213900-26-112236","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses entry into a definitive business combination agreement between Amanat Acquisition Corp (a SPAC) and Corxel US, a clinical-stage biopharmaceutical company. The press release announces the \"definitive business combination agreement\" with expected closing in H1 2027, involving approximately $377 million in gross proceeds ($75 million from Amanat's trust account plus $300 million PIPE financing). This is a material acquisition/change of control transaction that would substantially affect the registrant's business and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:14:42.868514+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":37756,"run_id":34794,"accession_number":"0001213900-26-112236","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Amanat disclosed unregistered sales of approximately $300 million in equity securities to institutional investors as part of the PIPE financing, including issuance of New Corxel Common Stock and PIPE Pre-Funded Warrants relying on Section 4(a)(2) exemption.","company_name":"Amanat Acquisition Corp.","ticker":"AMAN","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42574,"accession_number":"0001213900-26-112236","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses unregistered sales of equity securities in connection with a PIPE (private investment in public equity) of approximately $300 million, including issuance of New Corxel Common Stock and PIPE Pre-Funded Warrants relying on Section 4(a)(2) exemption. The press release confirms institutional investors have committed to this PIPE financing as part of the business combination transaction. This is a classic dilutive private placement of equity securities by a SPAC acquiring a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:14:42.868514+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42573,"accession_number":"0001213900-26-112236","item_number":"1.01","item_title":"Entry Into A Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This disclosure documents entry into a definitive Business Combination Agreement between Amanat Acquisition Corp (a SPAC) and Corxel Pharmaceuticals, Inc., involving a merger structure with an implied Corxel equity value of $200 million and approximately $377 million in gross proceeds (including a $300 million PIPE). The transaction is a material acquisition/change of control that will result in Corxel becoming a publicly listed company, with expected closing in H1 2027 subject to customary conditions including shareholder approval and HSR clearance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:14:42.868514+00:00","company_name":"Amanat Acquisition Corp.","ticker":"AMAN","filing_date":"2026-10-26"},{"id":42574,"accession_number":"0001213900-26-112236","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses unregistered sales of equity securities in connection with a PIPE (private investment in public equity) of approximately $300 million, including issuance of New Corxel Common Stock and PIPE Pre-Funded Warrants relying on Section 4(a)(2) exemption. The press release confirms institutional investors have committed to this PIPE financing as part of the business combination transaction. This is a classic dilutive private placement of equity securities by a SPAC acquiring a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:14:42.868514+00:00","company_name":"Amanat Acquisition Corp.","ticker":"AMAN","filing_date":"2026-10-26"},{"id":42575,"accession_number":"0001213900-26-112236","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses entry into a definitive business combination agreement between Amanat Acquisition Corp (a SPAC) and Corxel US, a clinical-stage biopharmaceutical company. The press release announces the \"definitive business combination agreement\" with expected closing in H1 2027, involving approximately $377 million in gross proceeds ($75 million from Amanat's trust account plus $300 million PIPE financing). This is a material acquisition/change of control transaction that would substantially affect the registrant's business and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:14:42.868514+00:00","company_name":"Amanat Acquisition Corp.","ticker":"AMAN","filing_date":"2026-10-26"}]}
